RxDoctor Payments Data

Joseph Fiorillo

Medical Oncology · Eugene, ORNPI 1427250505

Payments from drug & device makers

What this record shows

This record is dominated by education: $47 of the $47 with a category attached, or 100.0%. E.r. Squibb & Sons, L.L.C. accounts for 74.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in OR, where the typical reported total is $810.

$47in general payments, 2019–2025

Across 3 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$35
  • Gilead$12
$857,289in research payments, 2019–2025

Across 484 payments — averaging $1771.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$225K
  • E.r. Squibb & Sons, L.L.C.$190K
  • Seagen Inc.$188K
  • Bayer$102K
  • Roche Products Limited$54K
  • GSK$35K
  • plus $62K from 5 others

What the payments were for

  • Education$47100%

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.2$35
Gilead1$12

How this compares

$47 in reported general payments places this provider in the 15th percentile of 92 medical oncology providers in Oregon.

See all medical oncology providers in Oregon

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$11,491
Exemestane17$2,449
Anastrozole46$941
Ibandronate Sodium18$937
Acyclovir11$179

Paid to pharmacies, not to this prescriber.

Other medical oncology in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →